Literature DB >> 27588704

The oncolytic compound LTX-401 targets the Golgi apparatus.

Heng Zhou1,2,3,4,5, Allan Sauvat1,2,3,4, Lígia C Gomes-da-Silva1,2,3,4,6, Sylvère Durand1,2,3,4, Sabrina Forveille1,2,3,4, Kristina Iribarren1,2,3,4, Takahiro Yamazaki5,7,8,9, Sylvie Souquere10, Lucillia Bezu1,2,3,4,5, Kevin Müller1,2,3,4,5, Marion Leduc1,2,3,4, Peng Liu1,2,3,4,5, Liwei Zhao1,2,3,4,5, Aurélien Marabelle8, Laurence Zitvogel5,7,8,9, Øystein Rekdal11,12, Oliver Kepp1,2,3,4, Guido Kroemer1,2,3,4,13,14.   

Abstract

LTX-401 is an oncolytic amino acid derivative with potential immunogenic properties. Here, we demonstrate that LTX-401 selectively destroys the structure of the Golgi apparatus, as determined by means of ultrastructural analyses and fluorescence microscopic observation of cells expressing Golgi-targeted GFP reporters. Subcellular fractionation followed by mass spectrometric detection revealed that LTX-401 selectively enriched in the Golgi rather than in mitochondria or in the cytosol. The Golgi-dissociating agent Brefeldin A (BFA) reduced cell killing by LTX-401 as it partially inhibited LTX-401-induced mitochondrial release of cytochrome c and the activation of BAX. The cytotoxic effect of LTX-401 was attenuated by the double knockout of BAX and BAK, as well as the mitophagy-enforced depletion of mitochondria, yet was refractory to caspase inhibition. LTX-401 induced all major hallmarks of immunogenic cell death detectable with biosensor cell lines including calreticulin exposure, ATP release, HMGB1 exodus and a type-1 interferon response. Moreover, LTX-401-treated tumors manifested a strong lymphoid infiltration. Altogether these results support the contention that LTX-401 can stimulate immunogenic cell death through a pathway in which Golgi-localized LTX-401 operates upstream of mitochondrial membrane permeabilization.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27588704      PMCID: PMC5136493          DOI: 10.1038/cdd.2016.86

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  25 in total

1.  Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death.

Authors:  M C Wei; W X Zong; E H Cheng; T Lindsten; V Panoutsakopoulou; A J Ross; K A Roth; G R MacGregor; C B Thompson; S J Korsmeyer
Journal:  Science       Date:  2001-04-27       Impact factor: 47.728

2.  In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis.

Authors:  Shine Tu; Gavin P McStay; Louis-Martin Boucher; Tak Mak; Helen M Beere; Douglas R Green
Journal:  Nat Cell Biol       Date:  2005-12-18       Impact factor: 28.824

3.  Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins.

Authors:  A M Verhagen; P G Ekert; M Pakusch; J Silke; L M Connolly; G E Reid; R L Moritz; R J Simpson; D L Vaux
Journal:  Cell       Date:  2000-07-07       Impact factor: 41.582

Review 4.  Molecular mechanisms of regulated necrosis.

Authors:  Lorenzo Galluzzi; Oliver Kepp; Stefan Krautwald; Guido Kroemer; Andreas Linkermann
Journal:  Semin Cell Dev Biol       Date:  2014-02-26       Impact factor: 7.727

Review 5.  Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

Authors:  L Galluzzi; J M Bravo-San Pedro; I Vitale; S A Aaronson; J M Abrams; D Adam; E S Alnemri; L Altucci; D Andrews; M Annicchiarico-Petruzzelli; E H Baehrecke; N G Bazan; M J Bertrand; K Bianchi; M V Blagosklonny; K Blomgren; C Borner; D E Bredesen; C Brenner; M Campanella; E Candi; F Cecconi; F K Chan; N S Chandel; E H Cheng; J E Chipuk; J A Cidlowski; A Ciechanover; T M Dawson; V L Dawson; V De Laurenzi; R De Maria; K-M Debatin; N Di Daniele; V M Dixit; B D Dynlacht; W S El-Deiry; G M Fimia; R A Flavell; S Fulda; C Garrido; M-L Gougeon; D R Green; H Gronemeyer; G Hajnoczky; J M Hardwick; M O Hengartner; H Ichijo; B Joseph; P J Jost; T Kaufmann; O Kepp; D J Klionsky; R A Knight; S Kumar; J J Lemasters; B Levine; A Linkermann; S A Lipton; R A Lockshin; C López-Otín; E Lugli; F Madeo; W Malorni; J-C Marine; S J Martin; J-C Martinou; J P Medema; P Meier; S Melino; N Mizushima; U Moll; C Muñoz-Pinedo; G Nuñez; A Oberst; T Panaretakis; J M Penninger; M E Peter; M Piacentini; P Pinton; J H Prehn; H Puthalakath; G A Rabinovich; K S Ravichandran; R Rizzuto; C M Rodrigues; D C Rubinsztein; T Rudel; Y Shi; H-U Simon; B R Stockwell; G Szabadkai; S W Tait; H L Tang; N Tavernarakis; Y Tsujimoto; T Vanden Berghe; P Vandenabeele; A Villunger; E F Wagner; H Walczak; E White; W G Wood; J Yuan; Z Zakeri; B Zhivotovsky; G Melino; G Kroemer
Journal:  Cell Death Differ       Date:  2014-09-19       Impact factor: 15.828

6.  The oncolytic peptide LTX-315 triggers immunogenic cell death.

Authors:  H Zhou; S Forveille; A Sauvat; T Yamazaki; L Senovilla; Y Ma; P Liu; H Yang; L Bezu; K Müller; L Zitvogel; Ø Rekdal; O Kepp; G Kroemer
Journal:  Cell Death Dis       Date:  2016-03-10       Impact factor: 8.469

7.  The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization.

Authors:  Heng Zhou; Sabrina Forveille; Allan Sauvat; Valentina Sica; Valentina Izzo; Sylvère Durand; Kevin Müller; Peng Liu; Laurence Zitvogel; Øystein Rekdal; Oliver Kepp; Guido Kroemer
Journal:  Oncotarget       Date:  2015-09-29

8.  The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells.

Authors:  Liv-Marie Eike; Nannan Yang; Øystein Rekdal; Baldur Sveinbjørnsson
Journal:  Oncotarget       Date:  2015-10-27

9.  LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent.

Authors:  Ketil André Camilio; Oystein Rekdal; Baldur Sveinbjörnsson
Journal:  Oncoimmunology       Date:  2014-06-25       Impact factor: 8.110

10.  The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma.

Authors:  Liv-Marie Eike; Brynjar Mauseth; Ketil André Camilio; Øystein Rekdal; Baldur Sveinbjørnsson
Journal:  PLoS One       Date:  2016-02-16       Impact factor: 3.240

View more
  12 in total

1.  Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity.

Authors:  Kathleen M Kokolus; Jeremy S Haley; Emily J Koubek; Raghavendra Gowda; Saketh S Dinavahi; Arati Sharma; David F Claxton; Klaus F Helm; Joseph J Drabick; Gavin P Robertson; Jeffrey D Neighbors; Raymond J Hohl; Todd D Schell
Journal:  Oncoimmunology       Date:  2018-11-11       Impact factor: 8.110

Review 2.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.

Authors:  Lorenzo Galluzzi; Juliette Humeau; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

3.  Tumor lysis with LTX-401 creates anticancer immunity.

Authors:  Wei Xie; Laura Mondragón; Brynjar Mauseth; Yan Wang; Jonathan Pol; Sarah Lévesque; Heng Zhou; Takahiro Yamazaki; Johannes J Eksteen; Laurence Zitvogel; Baldur Sveinbjørnsson; Øystein Rekdal; Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2019-04-13       Impact factor: 8.110

4.  Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus.

Authors:  Lígia C Gomes-da-Silva; Liwei Zhao; Lucillia Bezu; Heng Zhou; Allan Sauvat; Peng Liu; Sylvère Durand; Marion Leduc; Sylvie Souquere; Friedemann Loos; Laura Mondragón; Baldur Sveinbjørnsson; Øystein Rekdal; Gaelle Boncompain; Franck Perez; Luis G Arnaut; Oliver Kepp; Guido Kroemer
Journal:  EMBO J       Date:  2018-05-28       Impact factor: 11.598

5.  Recruitment of LC3 to damaged Golgi apparatus.

Authors:  Lígia C Gomes-da-Silva; Ana Joaquina Jimenez; Allan Sauvat; Wei Xie; Sylvie Souquere; Séverine Divoux; Marko Storch; Baldur Sveinbjørnsson; Øystein Rekdal; Luis G Arnaut; Oliver Kepp; Guido Kroemer; Franck Perez
Journal:  Cell Death Differ       Date:  2018-10-22       Impact factor: 15.828

Review 6.  Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies.

Authors:  Oliver Kepp; Aurelien Marabelle; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2019-10-08       Impact factor: 66.675

Review 7.  Peptides that immunoactivate the tumor microenvironment.

Authors:  Natsuki Furukawa; Aleksander S Popel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-01       Impact factor: 10.680

8.  Squaramide-based synthetic chloride transporters activate TFEB but block autophagic flux.

Authors:  Shaoyi Zhang; Yan Wang; Wei Xie; Ethan N W Howe; Nathalie Busschaert; Allan Sauvat; Marion Leduc; Lígia C Gomes-da-Silva; Guo Chen; Isabelle Martins; Xiaxing Deng; Luigi Maiuri; Oliver Kepp; Thierry Soussi; Philip A Gale; Naoufal Zamzami; Guido Kroemer
Journal:  Cell Death Dis       Date:  2019-03-11       Impact factor: 8.469

9.  Functional disruption of the Golgi apparatus protein ARF1 sensitizes MDA-MB-231 breast cancer cells to the antitumor drugs Actinomycin D and Vinblastine through ERK and AKT signaling.

Authors:  Charlotte Luchsinger; Marcelo Aguilar; Patricia V Burgos; Pamela Ehrenfeld; Gonzalo A Mardones
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

10.  Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals.

Authors:  Heng Zhou; Laura Mondragón; Wei Xie; Brynjar Mauseth; Marion Leduc; Allan Sauvat; Lígia C Gomes-da-Silva; Sabrina Forveille; Kristina Iribarren; Sylvie Souquere; Lucillia Bezu; Peng Liu; Liwei Zhao; Laurence Zitvogel; Baldur Sveinbjørnsson; J Johannes Eksteen; Øystein Rekdal; Oliver Kepp; Guido Kroemer
Journal:  Cell Death Dis       Date:  2018-10-23       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.